Marshall Wace
ENTX icon

Marshall Wace’s Entera Bio ENTX Stock Holding History

Marshall Wace’s Portfolio ENTX Stock Details ENTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-195,780
Closed -$217K – 3315
2026
Q1 		$217K Sell
195,780
-431,550
-69% -$606K ﹤0.01% 2763
2025
Q4 		$1.22M Hold
627,330
– – ﹤0.01% 1833
2025
Q3 		$1.2M Buy
+627,330
New +$1.2M ﹤0.01% 1865

Other funds holding ENTX

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
SEIA
Signature Estate & Investment Advisors Los Angeles, California $5.56B AUM 26.66% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Marshall Wace's ENTX Position: Q2 2026 in Review

Marshall Wace sold out of Entera Bio (ENTX) in Q2 2026, closing a stake of 195,780 shares — an estimated $217K sold.

Marshall Wace first reported a position in ENTX in Q3 2025 and held it in 3 quarters. The position peaked at $1.22M in Q4 2025. 15 funds tracked by Wall St. Rank hold ENTX as of Q2 2026.

  • Marshall Wace reported no remaining Entera Bio position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 195,780 Entera Bio shares in Q2 2026, an estimated $217K.
  • Marshall Wace first reported a position in Entera Bio in Q3 2025 and held it in 3 quarters.
  • Marshall Wace's Entera Bio position peaked at $1.22M in Q4 2025.
  • 15 funds tracked by Wall St. Rank held Entera Bio as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.